Figure 6.
(A) Schematic drawings showing this experiment workflow. We injected mice with UM-UC-3 cells (2 × 105/tumor) and MGH-U-3 cells (5 × 105/tumor) together with Matrigel and divided them into three groups (n = 3; control (no treatment), n = 5; negative control siRNA, and n = 5 or 6; human DAB2 siRNA) after two weeks. Then, we treated mice twice a week for 4 weeks. Three days after the last treatment, we euthanized mice and harvested xenografts. Yellow triangles show subcutaneous tumors. (B) These pictures were xenografts resected from treatment groups. (C) Tumor growth rate during treatment was significantly lower in UM-UC-3 mice treated with DAB2 siRNA compared to both the control and negative control siRNA group (Mann–Whitney U test; * = p < 0.05). Intratumoral treatment with DAB2 siRNA resulted in a significant weight loss of excised xenografts compared to both the control and negative control siRNA group (Mann–Whitney U test; * = p < 0.05). However, in MGH-U-3 mice, both tumor growth rates and resected tumor weights were not significantly different between groups. (D) Representative images of xenograft tumors stained for each marker in UM-UC-3 group cells. Yellow triangles indicate tumor infiltration in control group mice but not in treatment group animals.